Remission in psoriatic arthritis: is it possible and how can it be predicted?

Hdl Handle:
http://hdl.handle.net/10147/120250
Title:
Remission in psoriatic arthritis: is it possible and how can it be predicted?
Authors:
Saber, Tajvur P; Ng, C T; Renard, Guillaume; Lynch, Bernadette M; Pontifex, Eliza; Walsh, Ceara A E; Grier, Alexia; Molloy, Marian; Bresnihan, Barry; Fitzgerald, Oliver; Fearon, Ursula; Veale, Douglas J
Affiliation:
Department of Rheumatology, Dublin Academic Medical Centre, St Vincent's University Hospital, and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Elm Park, Dublin 4, Ireland.
Citation:
Remission in psoriatic arthritis: is it possible and how can it be predicted? 2010, 12 (3):R94 Arthritis Res. Ther.
Journal:
Arthritis research & therapy
Issue Date:
2010
URI:
http://hdl.handle.net/10147/120250
DOI:
10.1186/ar3021
PubMed ID:
20482783
Abstract:
Since remission is now possible in psoriatic arthritis (PsA) we wished to examine remission rates in PsA patients following anti tumour necrosis factor alpha (TNFalpha) therapy and to examine possible predictors of response.; Analysis of a prospective patient cohort attending a biologic clinic, between November 2004 and March 2008, was performed prior to commencing therapy and at regular intervals. Baseline clinical characteristics including demographics, previous disease-modifying antirheumatic drug (DMARD) response, tender and swollen joint counts, early morning stiffness, pain visual analogue score, patient global assessment, C reactive protein (CRP) and health assessment questionnaire (HAQ) were collected.; A total of 473 patients (152 PsA; 321 rheumatoid arthritis (RA)) were analyzed. At 12 months remission, defined according to the disease activity score using 28 joint count and CRP (DAS28-CRP), was achieved in 58% of PsA patients compared to 44% of RA patients, significant improvement in outcome measures were noted in both groups (P<0.05). Analysis of a subgroup of PsA and RA patients matched for DAS28-CRP at baseline also showed higher numbers of PsA patients achieving remission. Linear regression analysis identified the HAQ at baseline as the best predictor of remission in PsA patients (P<0.001).; DAS28 remission is possible in PsA patients at one year following anti-TNF therapy, at higher rates than in RA patients and is predicted by baseline HAQ.
Item Type:
Article
Language:
en
Keywords:
MEDICAL TREATMENT; ARTHRITIS
MeSH:
Adolescent; Adult; Aged; Antibodies, Monoclonal; Arthritis, Psoriatic; Arthritis, Rheumatoid; C-Reactive Protein; Cohort Studies; Disease Progression; Female; Health Surveys; Humans; Immunoglobulin G; Linear Models; Male; Middle Aged; Outcome Assessment (Health Care); Predictive Value of Tests; Prospective Studies; Receptors, Tumor Necrosis Factor; Remission Induction; Retrospective Studies; Tumor Necrosis Factor-alpha; Young Adult
ISSN:
1478-6362

Full metadata record

DC FieldValue Language
dc.contributor.authorSaber, Tajvur Pen
dc.contributor.authorNg, C Ten
dc.contributor.authorRenard, Guillaumeen
dc.contributor.authorLynch, Bernadette Men
dc.contributor.authorPontifex, Elizaen
dc.contributor.authorWalsh, Ceara A Een
dc.contributor.authorGrier, Alexiaen
dc.contributor.authorMolloy, Marianen
dc.contributor.authorBresnihan, Barryen
dc.contributor.authorFitzgerald, Oliveren
dc.contributor.authorFearon, Ursulaen
dc.contributor.authorVeale, Douglas Jen
dc.date.accessioned2011-01-24T10:57:44Z-
dc.date.available2011-01-24T10:57:44Z-
dc.date.issued2010-
dc.identifier.citationRemission in psoriatic arthritis: is it possible and how can it be predicted? 2010, 12 (3):R94 Arthritis Res. Ther.en
dc.identifier.issn1478-6362-
dc.identifier.pmid20482783-
dc.identifier.doi10.1186/ar3021-
dc.identifier.urihttp://hdl.handle.net/10147/120250-
dc.description.abstractSince remission is now possible in psoriatic arthritis (PsA) we wished to examine remission rates in PsA patients following anti tumour necrosis factor alpha (TNFalpha) therapy and to examine possible predictors of response.-
dc.description.abstractAnalysis of a prospective patient cohort attending a biologic clinic, between November 2004 and March 2008, was performed prior to commencing therapy and at regular intervals. Baseline clinical characteristics including demographics, previous disease-modifying antirheumatic drug (DMARD) response, tender and swollen joint counts, early morning stiffness, pain visual analogue score, patient global assessment, C reactive protein (CRP) and health assessment questionnaire (HAQ) were collected.-
dc.description.abstractA total of 473 patients (152 PsA; 321 rheumatoid arthritis (RA)) were analyzed. At 12 months remission, defined according to the disease activity score using 28 joint count and CRP (DAS28-CRP), was achieved in 58% of PsA patients compared to 44% of RA patients, significant improvement in outcome measures were noted in both groups (P<0.05). Analysis of a subgroup of PsA and RA patients matched for DAS28-CRP at baseline also showed higher numbers of PsA patients achieving remission. Linear regression analysis identified the HAQ at baseline as the best predictor of remission in PsA patients (P<0.001).-
dc.description.abstractDAS28 remission is possible in PsA patients at one year following anti-TNF therapy, at higher rates than in RA patients and is predicted by baseline HAQ.-
dc.language.isoenen
dc.subjectMEDICAL TREATMENTen
dc.subjectARTHRITISen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshArthritis, Psoriatic-
dc.subject.meshArthritis, Rheumatoid-
dc.subject.meshC-Reactive Protein-
dc.subject.meshCohort Studies-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHealth Surveys-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin G-
dc.subject.meshLinear Models-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOutcome Assessment (Health Care)-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshProspective Studies-
dc.subject.meshReceptors, Tumor Necrosis Factor-
dc.subject.meshRemission Induction-
dc.subject.meshRetrospective Studies-
dc.subject.meshTumor Necrosis Factor-alpha-
dc.subject.meshYoung Adult-
dc.titleRemission in psoriatic arthritis: is it possible and how can it be predicted?en
dc.typeArticleen
dc.contributor.departmentDepartment of Rheumatology, Dublin Academic Medical Centre, St Vincent's University Hospital, and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Elm Park, Dublin 4, Ireland.en
dc.identifier.journalArthritis research & therapyen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.